



Nonprofit corporations and independent licensees
of the Blue Cross and Blue Shield Association

Medical benefit drug policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate certificate or contract for benefit information. This policy may be updated and therefore subject to change.

Effective Date: 10/12/2023

Scenesse® (afamelanotide injectable implant)

HCPCS: J7352

Policy:

Requests must be supported by submission of chart notes and patient specific documentation.

- A. Coverage of the requested drug is provided when all the following are met:
 - a. FDA approved indication
 - b. FDA approved age
 - c. Documentation of elevated erythrocyte metal-free protoporphyrin greater than or equal to 85% of the total erythrocyte protoporphyrin as determined by an accredited laboratory
OR
 - d. Documentation of a total erythrocyte protoporphyrin 50 – 100 times the upper limit of normal of the laboratory reference range as determined by an accredited laboratory
OR
 - e. Documentation of two mutations in the ferrochelatase (FECH) gene as determined by an accredited laboratory
 - f. Patient has documented symptoms of erythropoietic protoporphyria phototoxicity
 - g. No personal history of melanoma or other cancerous or precancerous skin lesions

- B. Quantity Limitations, Authorization Period and Renewal Criteria
 - a. Quantity Limits: Align with FDA recommended dosing
 - b. Authorization Period: 6 months at a time
 - c. Renewal Criteria: Documentation of improvement in the duration of sun exposure without pain

***Note: Coverage and approval duration may differ for Medicare Part B members based on any applicable criteria outlined in Local Coverage Determinations (LCD) or National Coverage Determinations (NCD) as determined by Center for Medicare and Medicaid Services (CMS). See the CMS website at <http://www.cms.hhs.gov/>. Determination of coverage of Part B drugs is based on medically accepted indications which have supported citations included or approved for inclusion determined by CMS approved compendia.

Background Information

- Scenesse is an alpha-melanocyte stimulating hormone analog indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP).

This policy and any information contained herein is the property of Blue Cross Blue Shield of Michigan and its subsidiaries, is strictly confidential, and its use is intended for the P&T committee, its members and BCBSM employees for the purpose of coverage determinations.

- EPP is an autosomal recessive, childhood-onset, rare porphyria with severe phototoxic manifestations. On sun exposure, patients experience prodromal symptoms, including tingling, burning, or itching, that serve as a warning signal, as continued exposure to sunlight leads to severe phototoxic pain and erythema and swelling of the exposed skin. The phototoxic pain is not responsive to treatment, including narcotic analgesics, and the severe pain may last for days. After experiencing the disabling phototoxic attacks, patients typically develop an ingrained fear of exposure to sunlight, leading to a conditioned behavior of sun avoidance that limits their daily activities and markedly impairs their quality of life.
- A diagnosis of EPP can be made in multiple ways if a patient is showing signs and symptoms of the disease. Biochemical testing is the most common method through which EPP is diagnosed via an elevated erythrocyte metal-free protoporphyrin greater than or equal to 85% of the total erythrocyte protoporphyrin level. Per Dr. Robert Desnick of Mount Sinai Hospital in New York City, an expert in EPP, diagnosis can also be made using the total erythrocyte protoporphyrin. He stated EPP will have a total erythrocyte protoporphyrin 50 to 100 times the upper limit of normal of the laboratory reference range. Finally, genetic testing can be done. Genetic testing will show two mutations of the ferrochelatase (FECH) gene. While there are over 200 known mutations of the FECH gene, 98% of EPP patients have an IVS3-48T>C variant. All biochemical and genetic testing should be performed in a laboratory that specializes in and is accredited in porphyria testing.
- The efficacy and safety of Scenesse was established in two Phase 3 studies. Patients in the United States and European Union were randomly assigned 1:1 to receive a subcutaneous implant of afamelanotide or placebo every 60 days for a six-month and a nine-month period, respectively. Patients in the US received 3 doses and those in the EU 5 doses. The study was designed to take place mostly during the summer months. The primary efficacy endpoint was duration of direct sunlight exposure between 10:00 am and 3:00 pm in the EU trial and 10:00 am and 6:00 pm in US trial on days when no pain was experienced (pain score of 0). There were 167 patients enrolled, 74 patients in the EU trial and 93 patients in the U.S. trial. Patients were excluded if they had a history of melanoma or other cancerous or precancerous skin lesions. In the United States, the median duration of pain-free time was longer over a 6-month period in the afamelanotide group compared to placebo (64.1 hours vs. 40.5 hours). In the European Union, the median duration of pain-free survival was longer over a 9-month period in the afamelanotide group compared to placebo (6.0 vs. 0.75).

References:

1. Scenesse [prescribing information]. West Menlo Park, CA: Clinuvel, Inc.; October 2022.
2. Langendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for erythropoietic protoporphyria. *NEJM*. 2015; 373: 48 – 59.
3. Balwani M. National Organization for Rare Diseases. Erythropoietic protoporphyria and x-linked protoporphyria. Available at: <https://rarediseases.org/rare-diseases/erythropoietic-protoporphyria/>. Accessed on: September 3, 2020.
4. Donker AE, Raymakers AEP, Valsveld LT, et al. Practice guidelines for the diagnosis and management of microcytic anemias due to genetic disorders of iron metabolism or heme synthesis. *Blood*. 2014 June 19; 123 (25): 3973 – 86.
5. Kushner JP and Phillips JD. Erythropoietic protoporphyria: multiple pathways to a common phenotype. *Hematologist*. 2013; 10 (5): 5 – 14.
6. Kopcke W and Krutmann J. Protection from sunburn with beta-carotene: a meta-analysis. *Photochem Photobiol*. 2008; 84 (2): 284.
7. Stozil U, Doss MO, and Schuppan D. Clinical guide and update on porphyrias. *Gastroenter*. 2019 August; 157 (2): 365 – 81.
8. Balwani M, Naik H, Anderson KE, et al. Clinical, biochemical, and genetic characterization of north american patients with erythropoietic protoporphyria and x-linked protoporphyria. *JAMA Dermatol*. 2017 Aug; 153 (8): 789 – 96.

Policy History												
#	Date	Change Description										
1.8	Effective Date: 10/12/2023	Annual review – no changes to criteria at this time										
1.7	Effective Date: 10/06/2022	Annual review – no changes to criteria at this time										
1.6	Effective Date: 10/07/2021	Annual review of criteria was performed, no changes were made.										
1.5	Effective Date: 10/08/2020	Updated testing requirements to allow genetic testing and use of total protoporphyrin and also added expert opinion										
1.4	Effective Date: 03/16/2020	UM medical management system update for MAPPO and BCNA <table border="1" data-bbox="483 548 1365 724"> <thead> <tr> <th>Line of Business</th> <th>PA Required (Yes/No)</th> </tr> </thead> <tbody> <tr> <td>BCBS</td> <td>Yes</td> </tr> <tr> <td>BCN</td> <td>Yes</td> </tr> <tr> <td>MAPPO</td> <td>Yes</td> </tr> <tr> <td>BCNA</td> <td>Yes</td> </tr> </tbody> </table>	Line of Business	PA Required (Yes/No)	BCBS	Yes	BCN	Yes	MAPPO	Yes	BCNA	Yes
Line of Business	PA Required (Yes/No)											
BCBS	Yes											
BCN	Yes											
MAPPO	Yes											
BCNA	Yes											
1.3	Effective Date: 1/1/2020	UM medical management system update for BCBS <table border="1" data-bbox="483 800 1365 1005"> <thead> <tr> <th>Line of Business</th> <th>PA Required in Medical Management System (Yes/No)</th> </tr> </thead> <tbody> <tr> <td>BCBS</td> <td>Yes</td> </tr> <tr> <td>BCN</td> <td>Yes</td> </tr> <tr> <td>MAPPO</td> <td>No</td> </tr> <tr> <td>BCNA</td> <td>No</td> </tr> </tbody> </table>	Line of Business	PA Required in Medical Management System (Yes/No)	BCBS	Yes	BCN	Yes	MAPPO	No	BCNA	No
Line of Business	PA Required in Medical Management System (Yes/No)											
BCBS	Yes											
BCN	Yes											
MAPPO	No											
BCNA	No											
1.2	Effective Date: 12/05/2019	Full drug review										
1.1	Effective Date: 11/15/2019	UM medical management system update for BCN <table border="1" data-bbox="483 1163 1365 1369"> <thead> <tr> <th>Line of Business</th> <th>PA Required in Medical Management System (Yes/No)</th> </tr> </thead> <tbody> <tr> <td>BCBS</td> <td>No</td> </tr> <tr> <td>BCN</td> <td>Yes</td> </tr> <tr> <td>MAPPO</td> <td>No</td> </tr> <tr> <td>BCNA</td> <td>No</td> </tr> </tbody> </table>	Line of Business	PA Required in Medical Management System (Yes/No)	BCBS	No	BCN	Yes	MAPPO	No	BCNA	No
Line of Business	PA Required in Medical Management System (Yes/No)											
BCBS	No											
BCN	Yes											
MAPPO	No											
BCNA	No											
1.0	Effective Date: 11/07/2019	Preliminary drug review <table border="1" data-bbox="483 1451 1365 1656"> <thead> <tr> <th>Line of Business</th> <th>PA Required in Medical Management System (Yes/No)</th> </tr> </thead> <tbody> <tr> <td>BCBS</td> <td>No</td> </tr> <tr> <td>BCN</td> <td>No</td> </tr> <tr> <td>MAPPO</td> <td>No</td> </tr> <tr> <td>BCNA</td> <td>No</td> </tr> </tbody> </table>	Line of Business	PA Required in Medical Management System (Yes/No)	BCBS	No	BCN	No	MAPPO	No	BCNA	No
Line of Business	PA Required in Medical Management System (Yes/No)											
BCBS	No											
BCN	No											
MAPPO	No											
BCNA	No											

* The prescribing information for a drug is subject to change. To ensure you are reading the most current information it is advised that you reference the most updated prescribing information by visiting the drug or manufacturer website or <http://dailymed.nlm.nih.gov/dailymed/index.cfm>.

This policy and any information contained herein is the property of Blue Cross Blue Shield of Michigan and its subsidiaries, is strictly confidential, and its use is intended for the P&T committee, its members and BCBSM employees for the purpose of coverage determinations.